Veeva Systems stock gets a 175 biotech growth signal

Published on 10/08/2026 at 03:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veeva Systems stock was last at USD 282.50 on October 7, while the company said more than 175 biotechs are adopting Veeva Basics. Fiscal Q2 revenue rose 17.6 percent.

VEEV, US9224751084, Illustration mit AI erstellt.

Veeva Systems stock (ISIN US9224751084) was last at USD 282.50 on the NYSE on October 7, 2026, down 0.35 percent from USD 283.50. The company said on October 7 that more than 175 emerging biotechs are establishing their technology foundation with Veeva Basics, adding a fresh commercial signal to the stock's recent software and data momentum.

Veeva expands its biotech reach

According to Veeva Systems on October 7, 2026, the pre-configured applications cover clinical, regulatory, quality, medical and commercial functions. The company said customers can launch the applications in weeks, which positions the product as an entry point for smaller biotechs that may later expand across the Vault platform.

The announcement also points to a broader adoption strategy. Veeva Basics supports regulatory publishing and health-authority interactions, while Veeva serves more than 1,500 customers across the life sciences industry, according to the company release.

Q2 growth came with a higher outlook

Veeva's fiscal Q2 2027 ended July 31, 2026, with revenue of USD 928.0 million, up 17.6 percent from the year-ago quarter, according to Financial Report Insights. GAAP net income reached USD 273.4 million, up 36.5 percent, and diluted GAAP EPS was USD 1.66, up 39.5 percent.

The profit comparison needs a qualification. The year-ago quarter included a USD 30.6 million litigation settlement-related charge, so the 36.5 percent net-income increase does not represent the full underlying operating trend; non-GAAP operating margin was 44.8 percent in fiscal Q2 2027 versus 44.7 percent a year earlier.

Management raised fiscal 2027 revenue guidance to USD 3.682 billion to USD 3.687 billion from USD 3.635 billion to USD 3.645 billion. The company also guided fiscal Q3 revenue to USD 932 million to USD 935 million, keeping the next checkpoint centered on whether Commercial Solutions growth can maintain its pace while customers migrate to Vault CRM.

Analysts see limited upside

MarketBeat reported on September 30, 2026, that 28 analysts held a Moderate Buy consensus, including 19 Buy ratings, eight Holds and one Sell rating. The average 12-month price target was USD 284.88, which is 0.84 percent above the USD 282.50 reference price.

The small gap between the stock and the average target makes execution more important than the rating label. Veeva's 52-week range was USD 148.05 to USD 308.36, placing the last price 8.39 percent below the high while the market capitalization stood at USD 45.9 billion.

Veeva Systems stock stays near its yearly high

VEEV was last at USD 282.50 on the NYSE on October 7, 2026, at 4:01 p.m. ET, with volume of 1,118,315 shares. The current setup combines a new customer-adoption figure, double-digit reported growth and a valuation that remains near the upper end of its annual range.